Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Neuroendocrine marker staining pattern categorization of small-sized pulmonary large cell neuroendocrine carcinoma.

Tytuł:
Neuroendocrine marker staining pattern categorization of small-sized pulmonary large cell neuroendocrine carcinoma.
Autorzy:
Minami K; Division of Thoracic Surgery, Kobe University Graduate School of Medicine, Kobe City, Japan.
Tanaka Y; Division of Thoracic Surgery, Kobe University Graduate School of Medicine, Kobe City, Japan.
Ogawa H; Department of Thoracic Surgery, Hyogo Cancer Center, Akashi City, Japan.
Jimbo N; Department of Diagnostic Pathology, Kobe University Graduate School of Medicine, Kobe City, Japan.
Nishio W; Department of Thoracic Surgery, Hyogo Cancer Center, Akashi City, Japan.
Yoshimura M; Department of Thoracic Surgery, Hyogo Cancer Center, Akashi City, Japan.
Itoh T; Department of Diagnostic Pathology, Kobe University Graduate School of Medicine, Kobe City, Japan.
Maniwa Y; Division of Thoracic Surgery, Kobe University Graduate School of Medicine, Kobe City, Japan.
Źródło:
Thoracic cancer [Thorac Cancer] 2019 Nov; Vol. 10 (11), pp. 2152-2160. Date of Electronic Publication: 2019 Oct 03.
Typ publikacji:
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Publication: November 2012- : Singapore : Tianjin : Wiley Publishing Asia Pty Ltd ; Tianjin Lung Cancer Institute
Original Publication: Richmond, Vic. : Tianjin : Blackwell Pub. Asia Pty Ltd. ; Tianjin Lung Cancer Institute
MeSH Terms:
Biomarkers, Tumor/*metabolism
Carcinoma, Large Cell/*surgery
Carcinoma, Neuroendocrine/*surgery
Lung Neoplasms/*surgery
Small Cell Lung Carcinoma/*pathology
Adult ; Aged ; Aged, 80 and over ; Carcinoma, Large Cell/metabolism ; Carcinoma, Large Cell/pathology ; Carcinoma, Neuroendocrine/metabolism ; Carcinoma, Neuroendocrine/pathology ; Chromogranin A/metabolism ; Female ; Humans ; Lung Neoplasms/metabolism ; Lung Neoplasms/pathology ; Lymph Node Excision ; Male ; Middle Aged ; Multivariate Analysis ; Neural Cell Adhesion Molecules/metabolism ; Prognosis ; Small Cell Lung Carcinoma/metabolism ; Small Cell Lung Carcinoma/surgery ; Survival Analysis ; Synaptophysin/metabolism ; Tumor Burden
References:
Ann Oncol. 2010 Oct;21 Suppl 7:vii65-71. (PMID: 20943645)
J Natl Compr Canc Netw. 2018 Oct;16(10):1171-1182. (PMID: 30323087)
J Thorac Oncol. 2009 Sep;4(9):1049-59. (PMID: 19652623)
J Clin Oncol. 2006 Jan 1;24(1):70-6. (PMID: 16382115)
Clin Cancer Res. 2017 Feb 1;23(3):757-765. (PMID: 27507618)
J Thorac Cardiovasc Surg. 2006 Aug;132(2):312-5. (PMID: 16872955)
J Thorac Oncol. 2018 Jun;13(6):752-766. (PMID: 29454048)
Cancer. 2008 Jul 1;113(1):5-21. (PMID: 18473355)
Hum Pathol. 2014 May;45(5):1045-56. (PMID: 24746210)
Lancet. 2004 Mar 6;363(9411):775-81. (PMID: 15016488)
J Thorac Cardiovasc Surg. 2013 Mar;145(3):839-46. (PMID: 22498090)
J Thorac Oncol. 2010 Feb;5(2):215-9. (PMID: 20101146)
Clin Cancer Res. 2016 Jul 15;22(14):3618-29. (PMID: 26960398)
Eur J Cardiothorac Surg. 2013 Jan;43(1):111-4. (PMID: 22529187)
J Thorac Cardiovasc Surg. 2002 Aug;124(2):285-92. (PMID: 12167788)
Am J Surg Pathol. 1998 Aug;22(8):934-44. (PMID: 9706973)
Nat Commun. 2018 Mar 13;9(1):1048. (PMID: 29535388)
Am J Surg Pathol. 1991 Jun;15(6):529-53. (PMID: 1709558)
J Thorac Oncol. 2015 Sep;10(9):1240-1242. (PMID: 26291007)
J Thorac Oncol. 2015 Sep;10(9):1243-1260. (PMID: 26291008)
Eur J Cardiothorac Surg. 2012 Apr;41(4):841-6. (PMID: 22219429)
J Thorac Oncol. 2015 Dec;10(12):1675-84. (PMID: 26709477)
Ann Thorac Surg. 2015 Mar;99(3):983-9. (PMID: 25596870)
Gen Thorac Cardiovasc Surg. 2014 Jun;62(6):351-6. (PMID: 24719260)
Ann Thorac Surg. 2002 Apr;73(4):1049-54. (PMID: 11996239)
Contributed Indexing:
Keywords: Immunostaining; large cell neuroendocrine carcinoma; neuroendocrine markers; small cell lung carcinoma; small-sized tumors
Substance Nomenclature:
0 (Biomarkers, Tumor)
0 (CHGA protein, human)
0 (Chromogranin A)
0 (Neural Cell Adhesion Molecules)
0 (SYP protein, human)
0 (Synaptophysin)
Entry Date(s):
Date Created: 20191005 Date Completed: 20200727 Latest Revision: 20200727
Update Code:
20240104
PubMed Central ID:
PMC6825905
DOI:
10.1111/1759-7714.13202
PMID:
31583856
Czasopismo naukowe
Background: The aim of this study was to identify subgroups with good or bad prognosis in patients with pulmonary large cell neuroendocrine carcinoma (LCNEC) based on immunostaining patterns with neuroendocrine markers and compare them with small cell lung carcinoma (SCLC).
Methods: From January 2001 to December 2017, of all patients with resected LCNEC and SCLC, we selected patients whose pathological tumor sizes were ≤30 mm in diameter (defined as small-sized tumors) and who underwent complete resection with lymphadenectomy. We classified patients with small-sized LCNEC (sLCNEC) into two subgroups based on immunostaining patterns with three neuroendocrine markers (chromogranin A, synaptophysin, and NCAM) and compared them to small-sized SCLC (sSCLC).
Results: A total of 48 patients with sLCNEC and 39 patients with sSCLC were enrolled. Of 48 patients with sLCNEC, 21 were categorized as the small-sized triple-positive group (sTP), whose patients were positive for the three neuroendocrine markers, and 27 patients were categorized as the small-sized nontriple-positive group (sNTP), whose patients were not positive for all three neuroendocrine markers. The percentage of lymph node metastasis was significantly lower in sNTP than in sTP and sSCLC. There was no significant difference in overall survival, but recurrence-free survival (RFS) and tumor-specific survival (TSS) were significantly poorer in sTP and sSCLC than in sNTP. Multivariate analysis revealed sTP and sSCLC were independent prognostic factors for poorer RFS and TSS than those of sNTP.
Conclusions: The sNTP subgroup had a good prognosis and the sTP subgroup a poor prognosis. There were some similarities in clinicopathological features between sTP and sSCLC.
(© 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.)
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies